IMMUNITYBIO, INC. Payments to Acquire Interest in Joint Venture
IMMUNITYBIO, INC. (IBRX) reported Payments to Acquire Interest in Joint Venture of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInterestInJointVenture · last filed 2025-03-03
- IMMUNITYBIO, INC. payments to acquire interest in joint venture for the quarter ending 2023-12-31 was $0.00.
- IMMUNITYBIO, INC. payments to acquire interest in joint venture for the quarter ending 2023-09-30 was $0.00.
- IMMUNITYBIO, INC. payments to acquire interest in joint venture for the quarter ending 2023-06-30 was $0.00.
- IMMUNITYBIO, INC. payments to acquire interest in joint venture for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. payments to acquire interest in joint venture for fiscal 2024 was $0.00.
- IMMUNITYBIO, INC. payments to acquire interest in joint venture for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- IMMUNITYBIO, INC. payments to acquire interest in joint venture for fiscal 2022 was $1.00M.
- IMMUNITYBIO, INC. payments to acquire interest in joint venture for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Interest in Joint Venture 3 month | Payments to Acquire Interest in Joint Venture 6 month | Payments to Acquire Interest in Joint Venture 9 month | Payments to Acquire Interest in Joint Venture 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | $0.00 derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | $0.00 derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | $1.00M 10-K · filed 2025-03-03 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $1.00M 10-Q · filed 2023-11-09 | $1.00M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.00M 10-Q · filed 2023-08-08 | $1.00M derived: sum of 3 quarters · filed 2024-03-19 | $1.00M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $1.00M 10-Q · filed 2023-05-11 | $1.00M derived: sum of 2 quarters · filed 2024-03-19 | $1.00M derived: sum of 3 quarters · filed 2024-03-19 | $1.00M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 derived: sum of 3 quarters · filed 2024-03-19 | $0.00 10-K · filed 2024-03-19 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |